ROWLAND LLOYD A 4
4 · CytomX Therapeutics, Inc. · Filed Jul 21, 2022
Insider Transaction Report
Form 4
ROWLAND LLOYD A
General Counsel
Transactions
- Sale
Common Stock
2022-07-20$1.42/sh−5,602$7,968→ 43,689 total - Award
Common Stock
2022-07-19+15,000→ 49,291 total
Footnotes (3)
- [F1]Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested.
- [F2]Includes 22,500 restricted stock units.
- [F3]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer.